Bioventus (NYSE:BVS) Upgraded at JPMorgan Chase & Co.

Bioventus (NYSE:BVS) was upgraded by stock analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a note issued to investors on Tuesday,Briefing.com Automated Import reports. The brokerage currently has a $13.00 price objective on the stock, up from their previous price objective of $12.00. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 16.59% from the company’s current price.

Other equities analysts also recently issued research reports about the company. Craig Hallum increased their price target on Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a report on Friday, September 27th. Canaccord Genuity Group upped their price objective on shares of Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th.

Bioventus Stock Up 1.1 %

Bioventus stock opened at $11.15 on Tuesday. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus has a 1-year low of $3.90 and a 1-year high of $14.38. The firm’s fifty day simple moving average is $12.08 and its 200-day simple moving average is $9.59. The company has a market capitalization of $904.88 million, a P/E ratio of -18.28 and a beta of 0.79.

Bioventus (NYSE:BVS) last posted its earnings results on Tuesday, November 5th. The company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. The company had revenue of $138.96 million for the quarter, compared to analyst estimates of $132.57 million. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. During the same period last year, the company earned $0.05 earnings per share. Sell-side analysts forecast that Bioventus will post 0.41 earnings per share for the current fiscal year.

Institutional Trading of Bioventus

Several hedge funds have recently added to or reduced their stakes in the business. Virtus Fund Advisers LLC acquired a new stake in Bioventus in the 3rd quarter worth $42,000. Quest Partners LLC acquired a new stake in Bioventus during the third quarter worth about $51,000. Quarry LP bought a new position in Bioventus during the third quarter valued at about $59,000. HB Wealth Management LLC acquired a new position in Bioventus in the 2nd quarter valued at approximately $60,000. Finally, Covestor Ltd bought a new stake in shares of Bioventus in the 3rd quarter worth approximately $69,000. Institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.